Ophthalmology
-
Randomized Controlled Trial Multicenter Study Comparative Study
GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial.
Pathologic corneal neovascularization not only reduces corneal transparency and visual acuity, but also is one of the most significant preoperative and postoperative risk factors for graft rejection after corneal transplantation. The aim of this study was to test tolerability and efficacy of gene signal (GS)-101 eye drops, an antisense oligonucleotide against insulin receptor substrate-1, versus placebo on inhibition of progressive corneal neovascularization. ⋯ Proprietary or commercial disclosure may be found after the references.
-
To report a possible association between fluoroquinolones and diplopia. ⋯ Proprietary or commercial disclosure may be found after the references.